Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$10.15
-0.10 (-0.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.7B · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12.2B
P/E
17.2x
↓EV/EBITDA
7.2x
↓ROE
6.3%
↑Gross Margin
44.8%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.5%
FCF CAGR
+0.7%
FCF margin
15.7%
FCF / Net income
3.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.55B · net income $540.7M · FCF $1.66B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.55B | $10.55B | $10.34B | $10.05B | $11.38B |
| Net Income | $540.7M | $540.7M | $601.2M | $-93.2M | $488.9M |
| EBITDA | $1.89B | $1.89B | $1.96B | $1.18B | $2.01B |
| EPS | 0.46 | 0.46 | 0.52 | -0.08 | 0.41 |
| Gross Margin | 44.8% | 44.8% | 42.5% | 41.5% | 44.2% |
| Operating Margin | 12.1% | 12.1% | 9.8% | 5.2% | 10.0% |
| Net Margin | 5.1% | 5.1% | 5.8% | -0.9% | 4.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.51 | 0.70 | 0.76 |
| Current Ratio | 1.00 | 1.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.66B | $1.66B | $1.95B | $1.22B | $1.62B |
| Returns | |||||
| ROE | 6.3% | 6.3% | 7.2% | -1.1% | 6.1% |
| Valuation | |||||
| P/E | 17.20 | 17.20 | 15.60 | — | 26.91 |
| EV/EBITDA | 7.24 | 7.24 | 6.18 | 12.87 | 8.73 |
| P/B | 1.39 | 1.39 | 1.12 | 1.37 | 1.58 |
| Growth & Yield | |||||
| Revenue Growth | 2.0% | 2.0% | 2.9% | -11.7% | — |
| EPS Growth | -11.5% | -11.5% | 774.1% | -118.9% | — |
| Dividend Yield | 1.9% | 1.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
25.1%
EPS terminal req.
$0.90
Spread vs growth
-36.6%
5Y implied EPS CAGR
18.8%
EPS terminal req.
$1.09
Spread vs growth
-30.4%
10Y implied EPS CAGR
14.3%
EPS terminal req.
$1.76
Spread vs growth
-25.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.7%
Start / end P/E
16.8x → 22.1x
EPS bridge
0.52 → 0.46
Residual
-3.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.